Osteoporosis: Treatment Guidelines & Prescriptions for Specific Scenarios

Disclaimer: The prescriptions below are illustrative clinical examples based on current guidelines. They must be adapted to individual patient comorbidities, local formulary, renal function, and clinical judgment. Always verify current dosing references before prescribing.

1. Diagnosis & Treatment Thresholds

• Calcium: 1,000–1,200 mg/day (diet preferred; supplement if needed)
• Vitamin D: 800–1,000 IU/day (vitamin D3); target 25-OH-D ≥ 30 ng/mL

2. Drug Classes (2025 Guidelines)

A. Bisphosphonates — First-Line (ACP 2023 update)

• Take with 6–8 oz plain water only
• ≥30 min before food/drink/medications (60 min for ibandronate)
• Remain upright for ≥30 min afterward (60 min for ibandronate)

B. RANKL Inhibitor — Second-Line / High-Risk Alternative

• Dose: 60 mg SC every 6 months
• Approved for postmenopausal osteoporosis, osteoporosis in men, GC-induced osteoporosis, and cancer treatment-associated bone loss
• Bone density continues to increase beyond 4–5 years (unlike bisphosphonates); up to 21.7% spine BMD gain at 10 years
• Reduces vertebral fractures 68%, hip fractures 40%, nonvertebral 20%
• ACP 2023: now second-line — for patients intolerant of or with contraindications to bisphosphonates
• Critical: On discontinuation, rebound bone loss occurs — must transition to bisphosphonate for ≥1 year
• Avoid if eGFR <30 mL/min without careful calcium monitoring; can be used at eGFR <35 mL/min (unlike bisphosphonates)

C. Anabolic Agents — Very High-Risk / Severe Osteoporosis

Teriparatide (Forteo)

• Dose: 20 mcg SC once daily
• Duration: Up to 2 years (FDA previously limited; registry data show no increased osteosarcoma risk in humans — restriction lifted in USA; many countries still cap at 2 years)
• Mechanism: PTH 1-34 analog → stimulates osteoblasts, increases bone microarchitecture
• Reduces vertebral fractures ~50% vs risedronate in high-risk patients
• Side effects: injection site reactions, orthostatic hypotension, hypercalcemia, nausea
• Must follow with antiresorptive (bisphosphonate or denosumab) to maintain gains

Abaloparatide (Tymlos)

• Dose: 80 mcg SC once daily
• Duration: Up to 2 years
• PTHrP analog; similar mechanism to teriparatide with possibly less hypercalcemia
• Can cause hyperuricemia
• Must follow with antiresorptive

Romosozumab (Evenity) — Dual action

• Dose: 210 mg SC once monthly (given as two 105 mg injections)
• Duration: 12 months only
• Mechanism: anti-sclerostin antibody → increases bone formation AND decreases resorption
• ⚠️ Cardiovascular warning: Avoid in patients with MI or stroke in the previous year; increased CV events in clinical trials
• Indicated: postmenopausal women at very high fracture risk
• Must follow with antiresorptive (bisphosphonate) after completing 12 months

D. SERMs

• Dose: 60 mg PO daily
• Reduces vertebral fracture risk (not hip)
• Additional benefit: reduces invasive breast cancer risk
• Avoid if: thromboembolic history, at risk for cardiovascular disease
• Less potent antiresorptive than bisphosphonates — use in selected postmenopausal women

E. Hormone Therapy (Estrogen/HRT)

• No longer first-line for osteoporosis
• Reduces hip and clinical spine fractures by 34% and all fractures by 24% (WHI)
• Risks: ↑MI (+29%), ↑stroke (+40%), ↑VTE (+100%), ↑breast cancer (+26%)
• Consider only if menopausal symptoms + fracture risk; ideally started <60 years or within 10 years of menopause

3. Treatment Algorithm (ACP/AACE 2023–2025)

Confirm osteoporosis or high fracture risk (FRAX, BMD)
            ↓
Correct calcium & vitamin D deficiency
Lifestyle: weight-bearing exercise, fall prevention, smoking cessation
            ↓
FIRST-LINE: Bisphosphonate
(Alendronate 70mg/wk PO OR Zoledronic acid 5mg/yr IV)
            ↓ after 3–5 years
Reassess FRAX + BMD
  → Low-moderate risk: Drug holiday (oral 5yr / IV 3yr)
  → High risk: Continue OR switch
            ↓
SECOND-LINE (intolerance/contraindication):
Denosumab 60mg SC q6 months
(Always transition to bisphosphonate on discontinuation)
            ↓
VERY HIGH RISK or failed antiresorptive:
Anabolic agent → Romosozumab 12mo OR Teriparatide/Abaloparatide 2yr
            ↓
ALWAYS follow anabolic with antiresorptive (bisphosphonate)

4. Specific Clinical Scenario Prescriptions

Scenario 1: Postmenopausal Woman, Age 65, T-score −2.6, No Prior Fracture

Rx: Alendronate sodium 70 mg tablet
    Take ONE tablet orally once weekly (e.g., every Monday morning)
    With 8 oz plain water, at least 30 minutes before food or other medications
    Remain upright for 30 minutes after taking
    
Rx: Calcium Carbonate 500 mg + Vitamin D3 400 IU tablet
    Take TWO tablets daily with meals
    (Total: 1,000 mg Ca + 800 IU D3/day)
    
Monitoring: BMD at 2 years; Reassess at 5 years for drug holiday eligibility

Scenario 2: Postmenopausal Woman, Age 68, GERD/Esophageal Disease — Cannot Take Oral Bisphosphonates

Rx: Zoledronic acid (Reclast) 5 mg/100 mL IV infusion
    Administer once yearly as a 15-minute IV infusion
    Prehydrate patient; give acetaminophen 1g + ibuprofen 400mg 
    to reduce acute-phase reaction (flu-like symptoms in ~30%)
    
    Duration: 3 years, then reassess
    
Rx: Calcium + Vitamin D3 as above
    (Must give Ca+D supplements prior to infusion — correct hypocalcemia first)
    
Note: Check renal function (eGFR); avoid if eGFR <35 mL/min

Scenario 3: Male Patient, Age 72, T-score −2.8, Idiopathic Osteoporosis

Rx: Alendronate sodium 70 mg tablet
    Once weekly orally (same instructions as above)
    
    OR if IV preferred:
    Zoledronic acid 5 mg IV once yearly
    
Rx: Calcium 1,000 mg + Vitamin D3 800–1,000 IU daily

Check: Secondary causes — testosterone, TSH, parathyroid, celiac, 24hr urine Ca

Scenario 4: Postmenopausal Woman, Multiple Vertebral Fractures, T-score −3.2 — Very High Risk

Rx: Teriparatide (Forteo) 20 mcg/0.08 mL subcutaneous injection
    Inject once daily into thigh or abdominal wall
    Duration: Up to 2 years
    
    Side effect counseling: Sit/lie down after first few doses 
    (orthostatic hypotension); nausea, dizziness usually transient
    
THEN (on completion):
Rx: Zoledronic acid 5 mg IV once yearly
    Start within 1 month of last teriparatide dose
    Continue for minimum 3 years
    
Rx: Calcium 1,200 mg + Vitamin D3 800 IU daily throughout

Note: If patient had prior denosumab, teriparatide may be added;
avoid combination with oral bisphosphonate (can blunt anabolic effect)

Scenario 5: Postmenopausal Woman, Severe Osteoporosis, Recent Hip Fracture — Candidate for Romosozumab

Rx: Romosozumab (Evenity) 210 mg SC once monthly
    Administered as TWO separate 105 mg SC injections
    Duration: 12 months only
    
    ⚠️ Obtain CV history; CONTRAINDICATED if MI or stroke within 1 year
    Monitor: CV symptoms, injection site reactions, arthralgias
    
THEN (month 13 onward):
Rx: Alendronate 70 mg PO weekly
    OR Zoledronic acid 5 mg IV yearly
    Continue for 3–5 years minimum
    
Rx: Calcium 1,200 mg + Vitamin D3 800 IU daily throughout

Scenario 6: Glucocorticoid-Induced Osteoporosis (Prednisone ≥7.5 mg/day for ≥3 months)

FIRST: Risk-stratify by FRAX + baseline DEXA

LOW RISK (FRAX <10% major fracture, no prior fracture):
    Calcium 1,000–1,200 mg/day + Vitamin D3 600–800 IU/day
    Reassess annually

MODERATE–HIGH RISK or T-score ≤−2.5:
Rx: Zoledronic acid 5 mg IV once yearly
    (Preferred: superior efficacy vs. oral in GC users)
    OR
    Alendronate 70 mg PO weekly
    OR
    Risedronate 35 mg PO weekly
    
    Duration: For as long as glucocorticoid continues + re-evaluate at discontinuation
    
VERY HIGH RISK or T-score ≤−3.0 or vertebral fracture on steroids:
Rx: Teriparatide 20 mcg SC daily (superior to bisphosphonates in building bone)
    OR Abaloparatide 80 mcg SC daily
    Duration: 2 years, then bisphosphonate
    
    Denosumab 60 mg SC q6 months is an option if eGFR <35 (renal impairment)
    
Special note: eGFR <35 → avoid bisphosphonates; use denosumab
Children on GC (age 4–17): Calcium 1g + Vit D 600 IU/day; bisphosphonate if fracture history

Scenario 7: Postmenopausal Woman on Denosumab — Needs to Discontinue

CRITICAL: Rebound bone loss and vertebral fracture cascade occur if denosumab 
is stopped without transition therapy

TRANSITION PROTOCOL:
Rx: Zoledronic acid 5 mg IV single infusion
    Administer 6 months after the LAST denosumab injection
    (i.e., at the time the next denosumab dose would have been due)
    
    Repeat BMD + bone turnover markers (CTX) at 12 months
    If CTX still elevated, may repeat zoledronic acid at 12 months
    
    Continue monitoring annually

Scenario 8: Osteoporosis + Chronic Kidney Disease (eGFR 20–35)

Avoid: Oral and IV bisphosphonates (nephrotoxic at eGFR <35)

Rx: Denosumab (Prolia) 60 mg SC every 6 months
    Monitor serum calcium closely (risk of severe hypocalcemia in CKD)
    
Rx: Calcium supplementation 500–1,000 mg/day
    Active vitamin D analog: Calcitriol 0.25–0.5 mcg/day
    (Not regular vitamin D — CKD impairs activation)
    
Note: Teriparatide can be used in CKD stages 3–4 with caution 
(avoid if PTH >2× upper limit of normal — risk of adynamic bone disease)

5. Monitoring Summary

6. Recent Evidence Updates (PubMed 2023–2026)

• Sequential therapy meta-analysis (Nayak & Greenspan, Osteoporos Int, 2026; PMID: 41105226): Confirms anabolic-first → antiresorptive sequencing produces superior fracture protection vs. antiresorptive alone.
• Denosumab vs. oral bisphosphonates (Yang et al., Front Endocrinol, 2024; PMID: 39286276): Meta-analysis shows denosumab superior for spine BMD gains; similar nonvertebral fracture reduction.
• Male osteoporosis (Chen et al., Front Endocrinol, 2025; PMID: 40309441): Network meta-analysis — IV bisphosphonates and denosumab most effective in men.
• Bisphosphonate deprescribing (Jepsen et al., Eur Geriatr Med, 2023; PMID: 37393587): Most guidelines recommend drug holiday after 3–5 years in low-risk patients, but continuation in high-risk.